2nd Quarter - Report

POLSINELLI PC for TEVA PHARMACEUTICALS USA, INC.

Period 2nd Quarter 2019 Filed Jul 11, 2019 Signed by Karen Blitz

Official filing
Firm
POLSINELLI PC
Client
TEVA PHARMACEUTICALS USA, INC.
Income
$75,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
JAMES DAVIDSON —
JULIUS W HOBSON —
SYLVIA STANOJEV KORNEGAY —
HARRY ANASTASIOS SPORIDIS —
STEVEN STRANNE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 64 (116th), H.R. 1503 (116th), S. 1227 (116th), S. 1416 (116th), H.R. 1499 (116th), H.R. 1520 (116th), H.R. 938 (116th), H.R. 965 (116th), H.R. 2374 (116th), H.R. 2375 (116th), S. 1895 (116th), S. 1224 (116th), H.R. 2376 (116th), S. 340 (116th)

Pharmacy PHA

H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
JAMES DAVIDSON —
JULIUS W HOBSON —
SYLVIA STANOJEV KORNEGAY —
HARRY ANASTASIOS SPORIDIS —
STEVEN STRANNE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2376 (116th), S. 64 (116th), S. 1224 (116th), H.R. 1503 (116th), H.R. 1520 (116th), H.R. 1499 (116th), H.R. 2375 (116th), S. 340 (116th), S. 1416 (116th), H.R. 2374 (116th), S. 1895 (116th), H.R. 965 (116th), H.R. 938 (116th), S. 1227 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.